Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 13/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
| ▸ | CYP2E1 | P05181 | 7/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.56 |
| ▸ | TOP1 | P11387 | 1/20 | 0.55 |
| ▸ | PRF1 | P14222 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113973 | 0.82 | CYP2A6 (0.76) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL27956631 | 0.81 | CYP2A6 (0.69) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL29854440 | 0.80 | CYP2A6 (0.73) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL572604 | 0.79 | CYP2A6 (0.66) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL70783 | 0.79 | APP (0.67) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL3649267 | 0.78 | CYP2A6 (0.64) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL3649264 | 0.78 | CYP2A6 (0.64) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL13073856 | 0.78 | CYP2A6 (0.64) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL6850669 | 0.77 | CYP2A6 (0.62) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 | |
| SCHEMBL6850666 | 0.77 | CYP2A6 (0.62) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100343256-C | Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | claimed |
| CN-1678615-A | Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | claimed |
| US-8927551-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| CN-103951649-A | Heterocycle substituted hydroxamate aromatic amide compound or pharmaceutical acceptable salt thereof, and preparation method and application thereof | UNIV EAST CHINA NORMAL | 2014-07-30 | — | — | CN | disclosed |
| US-8609708-B2 | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-1998055479-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998055470-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| US-5430059-A | Treating heart disease | EISAI CO., LTD. (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0633248-A1 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0589491-A1 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5292770-A | Butenoic acid derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5166188-A | Cardiovascular disorders, antiischemic agents | EISAI CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| CN-1047860-A | BUTENOIC ACID DERIVATIVES | EISAI CO LTD (JP) | 1990-12-19 | — | — | CN | disclosed |
| EP-0399358-A2 | Butenoic acid derivatives | Eisai Co., Ltd. (JP) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | CYP2A6 3232/4885CYP2C19 1893/4885CYP3A4 2225/4885 |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | CYP2A6 284/4885CYP2C19 309/4885CYP3A4 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.